These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 33237558)

  • 21. [Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation].
    Li G; Chen J; Xu Z; Wang Y; Ding N; Peng L; Zhang C; Shao Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2017 Dec; 34(6):839-843. PubMed ID: 29188612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
    Mărginean A; Bănescu C; Moldovan V; Scridon A; Mărginean M; Bălaşa R; Maier S; Ţăruşi M; Dobreanu M
    Clin Appl Thromb Hemost; 2017 Apr; 23(3):255-265. PubMed ID: 26873108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy.
    Tatarunas V; Jankauskiene L; Kupstyte N; Skipskis V; Gustiene O; Grybauskas P; Lesauskaite V
    Blood Coagul Fibrinolysis; 2014 Jun; 25(4):369-74. PubMed ID: 24418943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.
    Klein MD; Lee CR; Stouffer GA
    Pharmacogenomics; 2018 Aug; 19(13):1039-1046. PubMed ID: 30028231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
    Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G
    Platelets; 2015; 26(6):558-62. PubMed ID: 25207801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Precision antiplatelet therapy for the prevention of ischaemic stroke.
    Wang D
    Stroke Vasc Neurol; 2022 Apr; 7(2):89-91. PubMed ID: 34716284
    [No Abstract]   [Full Text] [Related]  

  • 27. The effect of the CYP 2C19*2 polymorphism on stroke care.
    Nyírő G; Inczédy-Farkas G; Reményi V; Gál A; Pál Z; Molnár MJ
    Acta Physiol Hung; 2012 Mar; 99(1):33-9. PubMed ID: 22425806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of smoking on CYP2C19 genetic variants and clopidogrel efficacy in patients with minor stroke or transient ischaemic attack.
    Wang T; Pan Y; Lin J; Anand R; Wang D; Johnston SC; Meng X; Li H; Zhao X; Liu L; Wang Y; Wang Y;
    Eur J Neurol; 2019 Sep; 26(9):1175-1182. PubMed ID: 30974489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Lyu SQ; Yang YM; Zhu J; Wang J; Wu S; Zhang H; Shao XH; Ren JM
    Platelets; 2020 Nov; 31(8):971-980. PubMed ID: 32546030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
    AlMukdad S; Elewa H; Al-Badriyeh D
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile.
    Xu J; Wang A; Wangqin R; Mo J; Chen Z; Dai L; Meng X; Zhao X; Wang Y; Li H; Chen W; Xian Y; Wang Y;
    Ann Neurol; 2019 Sep; 86(3):419-426. PubMed ID: 31237713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
    Zhang J; Zhang J; Sun H; Ming T; Liu X; Cong Y; Li F; Li Z
    Int J Clin Pharmacol Ther; 2017 Oct; 55(10):789-797. PubMed ID: 28766499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia.
    Alhazzani AA; Munisamy M; Karunakaran G
    Neurosciences (Riyadh); 2017 Jan; 22(1):31-37. PubMed ID: 28064328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke].
    Sychev DA; Shprakh VV; Kitaeva EY; Mirzaev KB; Mickhalevich IM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(3. Vyp. 2):45-52. PubMed ID: 31184624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke.
    Bennett D; Yan B
    J Clin Neurosci; 2013 Jun; 20(6):767-70. PubMed ID: 23618682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of
    Tan K; Lian Z; Shi Y; Wang X; Yu H; Li M; Tian J; Ge Y
    Per Med; 2019 Jul; 16(4):301-312. PubMed ID: 31322488
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug resistance and secondary treatment of ischaemic stroke: The genetic component of the response to acetylsalicylic acid and clopidogrel.
    Gallego-Fabrega C; Krupinski J; Fernandez-Cadenas I;
    Neurologia; 2015; 30(9):566-73. PubMed ID: 24662033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
    Jiang M; You JH
    Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigating CYP2C19 loss-of-function allele statuses and their association with stroke of different etiologies in a Taiwanese population.
    Lee YC; Liao YC; Chang FC; Huang HC; Tsai JY; Chung CP
    J Chin Med Assoc; 2019 Jun; 82(6):469-472. PubMed ID: 30932939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implementation of Genotype-Guided Antiplatelet Therapy: Feasible but Not Without Obstacles.
    Lewis JP
    Circ Genom Precis Med; 2018 Apr; 11(4):e002118. PubMed ID: 29615455
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.